TAG-72 expression and clinical outcome in primary breast cancer.

C. Pizzi, A. Sgambato, M. De Laurentiis, G. Limite, L. Panico, G. Pettinato, R. Muraro, L. Tauchmanova, A. Galietta, A. R. Bianco, R. Mariani-Costantini, A. Contegiacomo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Clinical data of 92 patients with primary breast carcinomas previously analysed for the pattern of immunohistochemical expression of three distinct carbohydrate epitopes of the TAG-72 molecule were reviewed. The clinical outcome of the patients after a median follow-up of 66 months was determined in 84 out of 92 patients. Clinicopathological characteristics of the tumours and clinical outcome of the patients were correlated with the TAG-72 epitope expression. TAG-72 was expressed more frequently in patients aged more than 50 years and in tumours of larger size, with lymph nodes metastasis, with low differentiation and with high proliferative activity. A statistical correlation was found with more advanced stages of the disease (35.7% vs 60% in stage I and in stage II-III, respectively, p=0.03). Disease-free survival and overall survival were estimated by the Kaplan-Meier method. The survival of the patients with tumours expressing TAG-72 was not statistically different from that of patients with tumours without TAG-72 expression. These data suggest that TAG-72 expression is associated with clinicopathological parameters of aggressiveness in primary breast cancer, but it does not appear to affect the clinical outcome of the patients.

Original languageEnglish
Pages (from-to)1399-1403
Number of pages5
JournalOncology Reports
Volume6
Issue number6
Publication statusPublished - Nov 1999

Fingerprint

Breast Neoplasms
Epitopes
Neoplasms
Survival
tumor-associated antigen 72
Disease-Free Survival
Lymph Nodes
Carbohydrates
Neoplasm Metastasis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pizzi, C., Sgambato, A., De Laurentiis, M., Limite, G., Panico, L., Pettinato, G., ... Contegiacomo, A. (1999). TAG-72 expression and clinical outcome in primary breast cancer. Oncology Reports, 6(6), 1399-1403.

TAG-72 expression and clinical outcome in primary breast cancer. / Pizzi, C.; Sgambato, A.; De Laurentiis, M.; Limite, G.; Panico, L.; Pettinato, G.; Muraro, R.; Tauchmanova, L.; Galietta, A.; Bianco, A. R.; Mariani-Costantini, R.; Contegiacomo, A.

In: Oncology Reports, Vol. 6, No. 6, 11.1999, p. 1399-1403.

Research output: Contribution to journalArticle

Pizzi, C, Sgambato, A, De Laurentiis, M, Limite, G, Panico, L, Pettinato, G, Muraro, R, Tauchmanova, L, Galietta, A, Bianco, AR, Mariani-Costantini, R & Contegiacomo, A 1999, 'TAG-72 expression and clinical outcome in primary breast cancer.', Oncology Reports, vol. 6, no. 6, pp. 1399-1403.
Pizzi C, Sgambato A, De Laurentiis M, Limite G, Panico L, Pettinato G et al. TAG-72 expression and clinical outcome in primary breast cancer. Oncology Reports. 1999 Nov;6(6):1399-1403.
Pizzi, C. ; Sgambato, A. ; De Laurentiis, M. ; Limite, G. ; Panico, L. ; Pettinato, G. ; Muraro, R. ; Tauchmanova, L. ; Galietta, A. ; Bianco, A. R. ; Mariani-Costantini, R. ; Contegiacomo, A. / TAG-72 expression and clinical outcome in primary breast cancer. In: Oncology Reports. 1999 ; Vol. 6, No. 6. pp. 1399-1403.
@article{3faf7d9b26d74124b26ca52adb15db1b,
title = "TAG-72 expression and clinical outcome in primary breast cancer.",
abstract = "Clinical data of 92 patients with primary breast carcinomas previously analysed for the pattern of immunohistochemical expression of three distinct carbohydrate epitopes of the TAG-72 molecule were reviewed. The clinical outcome of the patients after a median follow-up of 66 months was determined in 84 out of 92 patients. Clinicopathological characteristics of the tumours and clinical outcome of the patients were correlated with the TAG-72 epitope expression. TAG-72 was expressed more frequently in patients aged more than 50 years and in tumours of larger size, with lymph nodes metastasis, with low differentiation and with high proliferative activity. A statistical correlation was found with more advanced stages of the disease (35.7{\%} vs 60{\%} in stage I and in stage II-III, respectively, p=0.03). Disease-free survival and overall survival were estimated by the Kaplan-Meier method. The survival of the patients with tumours expressing TAG-72 was not statistically different from that of patients with tumours without TAG-72 expression. These data suggest that TAG-72 expression is associated with clinicopathological parameters of aggressiveness in primary breast cancer, but it does not appear to affect the clinical outcome of the patients.",
author = "C. Pizzi and A. Sgambato and {De Laurentiis}, M. and G. Limite and L. Panico and G. Pettinato and R. Muraro and L. Tauchmanova and A. Galietta and Bianco, {A. R.} and R. Mariani-Costantini and A. Contegiacomo",
year = "1999",
month = "11",
language = "English",
volume = "6",
pages = "1399--1403",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - TAG-72 expression and clinical outcome in primary breast cancer.

AU - Pizzi, C.

AU - Sgambato, A.

AU - De Laurentiis, M.

AU - Limite, G.

AU - Panico, L.

AU - Pettinato, G.

AU - Muraro, R.

AU - Tauchmanova, L.

AU - Galietta, A.

AU - Bianco, A. R.

AU - Mariani-Costantini, R.

AU - Contegiacomo, A.

PY - 1999/11

Y1 - 1999/11

N2 - Clinical data of 92 patients with primary breast carcinomas previously analysed for the pattern of immunohistochemical expression of three distinct carbohydrate epitopes of the TAG-72 molecule were reviewed. The clinical outcome of the patients after a median follow-up of 66 months was determined in 84 out of 92 patients. Clinicopathological characteristics of the tumours and clinical outcome of the patients were correlated with the TAG-72 epitope expression. TAG-72 was expressed more frequently in patients aged more than 50 years and in tumours of larger size, with lymph nodes metastasis, with low differentiation and with high proliferative activity. A statistical correlation was found with more advanced stages of the disease (35.7% vs 60% in stage I and in stage II-III, respectively, p=0.03). Disease-free survival and overall survival were estimated by the Kaplan-Meier method. The survival of the patients with tumours expressing TAG-72 was not statistically different from that of patients with tumours without TAG-72 expression. These data suggest that TAG-72 expression is associated with clinicopathological parameters of aggressiveness in primary breast cancer, but it does not appear to affect the clinical outcome of the patients.

AB - Clinical data of 92 patients with primary breast carcinomas previously analysed for the pattern of immunohistochemical expression of three distinct carbohydrate epitopes of the TAG-72 molecule were reviewed. The clinical outcome of the patients after a median follow-up of 66 months was determined in 84 out of 92 patients. Clinicopathological characteristics of the tumours and clinical outcome of the patients were correlated with the TAG-72 epitope expression. TAG-72 was expressed more frequently in patients aged more than 50 years and in tumours of larger size, with lymph nodes metastasis, with low differentiation and with high proliferative activity. A statistical correlation was found with more advanced stages of the disease (35.7% vs 60% in stage I and in stage II-III, respectively, p=0.03). Disease-free survival and overall survival were estimated by the Kaplan-Meier method. The survival of the patients with tumours expressing TAG-72 was not statistically different from that of patients with tumours without TAG-72 expression. These data suggest that TAG-72 expression is associated with clinicopathological parameters of aggressiveness in primary breast cancer, but it does not appear to affect the clinical outcome of the patients.

UR - http://www.scopus.com/inward/record.url?scp=0033227507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033227507&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 1399

EP - 1403

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 6

ER -